menu
    • menu
    [{"orgOrder":0,"company":"PCI Pharma Services","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Lenzilumab","moa":"GM-CSF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PCI Pharma Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PCI Pharma Services \/ PCI Pharma Services","highestDevelopmentStatusID":"10","companyTruncated":"PCI Pharma Services \/ PCI Pharma Services"}]

    Find Clinical Drug Pipeline Developments & Deals by PCI Pharma Services

    Menu

    PCI Pharma Services

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    PCI Pharma Services

    U.S.A arrow
    Next-Gen Conjugates
    Not Confirmed

    PCI Pharma Services

    U.S.A arrow
    Next-Gen Conjugates
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lenzilumab,Remdesivir

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase II

    Recipient : Humanigen

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the ...

    Details : Under the agreement, PCI will purchase Humaneered (lenzilumab), for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19.

    Product Name : Humaneered

    Product Type : Large molecule

    Upfront Cash : Undisclosed

    June 16, 2022

    Lead Product(s) : Lenzilumab,Remdesivir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Recipient : Humanigen

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth